Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal E max regressions.

MLA

Beumer, Jan H., et al. “Evaluating the Indotecan-Neutropenia Relationship in Patients with Solid Tumors by Population Pharmacokinetic Modeling and Sigmoidal E Max Regressions.” Cancer Chemotherapy and Pharmacology, vol. 91, no. 3, Mar. 2023, pp. 219–30. EBSCOhost, https://doi.org/10.1007/s00280-023-04509-8.

APA

Beumer, J. H., Kennard, B. C., Holleran, J. L., Moore, N., Zlott, J., Miller, B. M., Kummar, S., Chen, A., Doroshow, J., Park, W., Gobburu, J., & Dunn, A. (2023). Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal E max regressions. Cancer Chemotherapy and Pharmacology, 91(3), 219–230. https://doi.org/10.1007/s00280-023-04509-8

Chicago

Beumer, Jan H, Benjamin C Kennard, Julianne L Holleran, Nancy Moore, Jennifer Zlott, Brian M Miller, Shivaani Kummar, et al. 2023. “Evaluating the Indotecan-Neutropenia Relationship in Patients with Solid Tumors by Population Pharmacokinetic Modeling and Sigmoidal E Max Regressions.” Cancer Chemotherapy and Pharmacology 91 (3): 219–30. doi:10.1007/s00280-023-04509-8.